Zhejiang CONBA Pharmaceutical Co Ltd (600572) - Total Liabilities
Based on the latest financial reports, Zhejiang CONBA Pharmaceutical Co Ltd (600572) has total liabilities worth CN¥2.85 Billion CNY (≈ $417.57 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Zhejiang CONBA Pharmaceutical Co Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
Zhejiang CONBA Pharmaceutical Co Ltd - Total Liabilities Trend (2001–2025)
This chart illustrates how Zhejiang CONBA Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Zhejiang CONBA Pharmaceutical Co Ltd.
Zhejiang CONBA Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang CONBA Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Luoyang Longhua Heat Trans Energy
SHE:300263
|
China | CN¥3.92 Billion |
|
Guizhou Aviation Technical Development Co Ltd
SHG:688239
|
China | CN¥3.10 Billion |
|
SFL Corporation Ltd
NYSE:SFL
|
USA | $2.59 Billion |
|
Elang Mahkota Teknologi Tbk
JK:EMTK
|
Indonesia | Rp6.08 Trillion |
|
AeroSpace Technology of Korea
KQ:067390
|
Korea | ₩256.53 Billion |
|
CIE Automotive India Limited
NSE:CIEINDIA
|
India | Rs35.69 Billion |
|
Jiangsu Changfa Refrigeration Co Ltd
SHE:002413
|
China | CN¥1.88 Billion |
|
AKSO HEALTH GR. (SPADR)/3
F:8HX
|
Germany | €13.73 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Zhejiang CONBA Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Zhejiang CONBA Pharmaceutical Co Ltd (600572) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang CONBA Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang CONBA Pharmaceutical Co Ltd (2001–2025)
The table below shows the annual total liabilities of Zhejiang CONBA Pharmaceutical Co Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.83 Billion ≈ $414.44 Million |
-5.25% |
| 2024-12-31 | CN¥2.99 Billion ≈ $437.40 Million |
-23.13% |
| 2023-12-31 | CN¥3.89 Billion ≈ $569.02 Million |
+7.84% |
| 2022-12-31 | CN¥3.61 Billion ≈ $527.66 Million |
+6.04% |
| 2021-12-31 | CN¥3.40 Billion ≈ $497.61 Million |
-13.45% |
| 2020-12-31 | CN¥3.93 Billion ≈ $574.96 Million |
-20.10% |
| 2019-12-31 | CN¥4.92 Billion ≈ $719.60 Million |
-0.06% |
| 2018-12-31 | CN¥4.92 Billion ≈ $720.07 Million |
+37.59% |
| 2017-12-31 | CN¥3.58 Billion ≈ $523.36 Million |
-10.74% |
| 2016-12-31 | CN¥4.01 Billion ≈ $586.35 Million |
-19.92% |
| 2015-12-31 | CN¥5.00 Billion ≈ $732.16 Million |
+70.85% |
| 2014-12-31 | CN¥2.93 Billion ≈ $428.55 Million |
+57.26% |
| 2013-12-31 | CN¥1.86 Billion ≈ $272.52 Million |
-11.23% |
| 2012-12-31 | CN¥2.10 Billion ≈ $307.01 Million |
+55.60% |
| 2011-12-31 | CN¥1.35 Billion ≈ $197.30 Million |
+80.42% |
| 2010-12-31 | CN¥747.34 Million ≈ $109.36 Million |
-4.28% |
| 2009-12-31 | CN¥780.76 Million ≈ $114.25 Million |
+20.19% |
| 2008-12-31 | CN¥649.60 Million ≈ $95.06 Million |
-6.31% |
| 2007-12-31 | CN¥693.32 Million ≈ $101.45 Million |
+10.37% |
| 2006-12-31 | CN¥628.20 Million ≈ $91.93 Million |
+12.07% |
| 2005-12-31 | CN¥560.55 Million ≈ $82.03 Million |
+34.63% |
| 2004-12-31 | CN¥416.37 Million ≈ $60.93 Million |
+21.67% |
| 2003-12-31 | CN¥342.22 Million ≈ $50.08 Million |
+30.68% |
| 2002-12-31 | CN¥261.88 Million ≈ $38.32 Million |
-1.45% |
| 2001-12-31 | CN¥265.74 Million ≈ $38.89 Million |
-- |
About Zhejiang CONBA Pharmaceutical Co Ltd
Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research, development, production, and sales of pharmaceuticals and health products in mainland China. It offers medicines, Chinese patent medicines, chemical medicines, Chinese herbal medicine slices, and health products. The company also provides Chinese decoction pieces; over-the-counter medications; healthy consumer products, including nut… Read more